Clinical trial analysis reveals steady visual decline poorly correlated with lesion area in geographic atrophy, indicating anatomical size cannot predict functional vision loss.
Chroma and Spectri provide a unique data set of functional end points in GA that are relevant for future clinical trials. Patients with bilateral GA experienced a consistent decline in visual function over 48 weeks, but measures of visual function were not correlated strongly with GA lesion area. It is not possible to predict visual function outcomes from GA lesion size.
No takes yet. Share an insight, caveat, or question.
Heier et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: